Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-27T00:48:21.888Z Has data issue: false hasContentIssue false

24 - Aromatase Inhibitors for Assisted Reproduction

from PART II - INFERTILITY EVALUATION AND TREATMENT

Published online by Cambridge University Press:  04 August 2010

By
Mohamed F. M. Mitwally  and
Robert F. Casper
Edited by
Botros R. M. B. Rizk ,
Juan A. Garcia-Velasco ,
Hassan N. Sallam  and
Antonis Makrigiannakis
Botros R. M. B. Rizk
Affiliation:
University of South Alabama
Juan A. Garcia-Velasco
Affiliation:
Rey Juan Carlos University School of Medicine,
Hassan N. Sallam
Affiliation:
University of Alexandria School of Medicine
Antonis Makrigiannakis
Affiliation:
University of Crete
Get access

Summary

This chapter discusses the potential role of the new group of medications called “aromatase inhibitors” in assisted reproduction. In the past few years, aromatase inhibitors have emerged as promising agents for infertility treatment, particularly ovarian stimulation. We reported the first series in the literature of the successful application of an aromatase inhibitor for induction of ovulation in women with polycystic ovarian syndrome (PCOS) (1) and ovarian stimulation in women with ovulatory infertility, for example, unexplained infertility (2). Following this report, we showed the success of aromatase inhibition for controlled ovarian hyperstimulation (COH) (3–5), whether as a single- or multiple-dose administration (6), and suggested the potential application in various infertility treatments including assisted reproduction (7–13), with data on safety of the pregnancy outcome (14).

Since these first reports, more than a hundred clinical trials have been presented in international meetings, confirming our original findings, by investigators from all over the globe. Many peer-reviewed manuscripts (15–33) have already confirmed the success of aromatase inhibitors in various infertility applications. Currently, several multicenter clinical trials are running testing the clinical efficacy of aromatase inhibitors for infertility treatment including ovarian stimulation. In this chapter, we will discuss the potential role of aromatase inhibitors for assisted reproduction, presenting the theoretical benefits and the available evidence.

AROMATASE INHIBITORS

Blocking estrogen production by inhibiting the enzyme catalyzing its synthesis from androgens (aromatase enzyme) is a treatment modality that has been in clinical application for more than half a century since the development of the first generations of aromatase inhibitors including aminoglutethimide.

Keywords

aromatase inhibitorsassisted reproductioncontrolled ovarian hyperstimulationendometriosispolycystic ovarian syndromeestrogen-dependant malignancies
Type
Chapter
Information
Infertility and Assisted Reproduction , pp. 220 - 227
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Mitwally, MFM, Casper, RF. Aromatase inhibition: a novel method of ovulation induction in women with polycystic ovarian syndrome. Reprod Technol 2000; 10: 244–7.Google Scholar
Mitwally, MFM, Casper, RF. Use of an AI for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001; 75: 305–9.CrossRefGoogle Scholar
Mitwally, MFM, Casper, RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril 2002; 774: 776–80.CrossRefGoogle Scholar
Mitwally, MF, Casper, RF. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod 2003; 188: 1588–97.CrossRefGoogle Scholar
Mitwally, MF, Casper, RF. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynecol Investig 2004; 11: 406–15.CrossRefGoogle ScholarPubMed
Mitwally, MFM, Casper, RF. Single dose administration of the aromatase inhibitor, letrozole: a simple and convenient effective method of ovulation induction. Fertil Steril 2005; 83: 229–31.CrossRefGoogle Scholar
Mitwally, MF, Casper, RF. Potential of aromatase inhibitors for ovulation and superovulation induction in infertile women. Drugs 2006; 66(18) 66(17): 2149–60.CrossRefGoogle ScholarPubMed
Mitwally, MFM, Casper, RF. Letrozole for ovulation induction. Exp Rev Obstet Gynecol 2006; 1(1): 15–27.CrossRefGoogle Scholar
Casper, RF, Mitwally, MF. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 2006; 91: 760–71.CrossRefGoogle ScholarPubMed
Mitwally, MF, Casper, RF, Diamond, MP. The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment. Reprod Biol Endocrinol 2005; 3: 54.CrossRefGoogle ScholarPubMed
Mitwally, MF, Casper, RF. Aromatase inhibitors in ovulation induction. Semin Reprod Med 2004; 22(1): 61–78.Google ScholarPubMed
Mitwally, MF, Casper, RF. Aromatase inhibitors for the treatment of infertility. Expert Opin Investig Drugs 2003; 12(3): 353–71.CrossRefGoogle ScholarPubMed
Mitwally, MF, Casper, RF. Aromatase inhibition for ovarian stimulation: future avenues for infertility management. Curr Opin Obstet Gynecol 2002; 14(3): 255–63.CrossRefGoogle ScholarPubMed
Mitwally, MFM, Casper, RF. Pregnancy outcome after the use of an AI for induction of ovulation. Am J Obstet Gynecol 2005; 192: 381–6.CrossRefGoogle Scholar
Healey, S, Tan, SL, Tulandi, T, Biljan, MM. Effects of letrozole on superovulation with gonadotropins in women undergoing intrauterine insemination. Fertil Steril 2003; 806: 1325–9.CrossRefGoogle Scholar
Cortinez, A, Carvalho, I, Vantman, D, et al. Hormonal profile and endometrial morphology in letrozole-controlled ovarian hyperstimulation in ovulatory infertile patients. Fertil Steril 2005; 83(1): 110–5.CrossRefGoogle ScholarPubMed
Fatemi, HM, Kolibianakis, E, Tournaye, H, et al. Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reprod Biomed Online 2003; 75: 543–6.CrossRefGoogle Scholar
Al-Omari, WR, Sulaiman, WR, Al-Hadithi, N. Comparison of two AIs in women with clomiphene-resistant polycystic ovary syndrome. Int J Gynaecol Obstet 2004; 853: 289–91.CrossRefGoogle Scholar
Al-Fozan, H, Al-Khadouri, M, Tan, SL, Tulandi, T. A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertil Steril 2004; 82: 1561–3.CrossRefGoogle ScholarPubMed
Goswami, SK, Das, T, Chattopadhyay, R, et al. A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report. Hum Reprod 2004; 19: 2031–5.CrossRefGoogle ScholarPubMed
Garcia-Velasco, JA, Moreno, L, Pacheco, A, et al. The aromatase inhibitor, letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril 2005; 84: 82–7.CrossRefGoogle ScholarPubMed
Oktay, K, Buyuk, E, Libertella, N, Akar, M, Rosenwaks, Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23: 4347–53.CrossRefGoogle ScholarPubMed
Bayar, U, Tanrierdi, HA, Barut, A, et al. Letrozole vs. clomiphene citrate in patients with ovulatory infertility. Fertil Steril 2006; 85: 1045–8.CrossRefGoogle ScholarPubMed
Elnashar, A, Fouad, H, Eldosoky, M, et al. Letrozole induction of ovulation in women with clomiphene citrate-resistant polycystic ovary syndrome may not depend on the period of infertility, the body mass index, or the luteinizing hormone/follicle stimulating hormone ratio. Fertil Steril 2006; 85: 161–4.CrossRefGoogle ScholarPubMed
Atay, V, Cam, C, Muhcu, M, et al. Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Int Med Res 2006; 34: 73–6.CrossRefGoogle ScholarPubMed
Sohrabvand, F, Ansari, S, Bagheri, M. Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease. Hum Reprod 2006; 21: 1432–5.CrossRefGoogle ScholarPubMed
Sipe, CS, Davis, WA, Maifeld, M, Voorhis, BJ. A prospective randomized trial comparing anastrozole and clomiphene citrate in an ovulation induction protocol using gonadotropins. Fertil Steril 2006; Sep 26; [Epub ahead of print].CrossRefGoogle Scholar
Bayar, U, Basaran, M, Kiran, S, Coskun, A, Gezer, S. Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial. Fertil Steril 2006; 86(5): 1447–51.CrossRefGoogle ScholarPubMed
Barroso, G, Menocal, G, Felix, H, Rojas-Ruiz, JC, Arslan, M, Oehninger, S. Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphene citrate as adjuvants to recombinant follicle-stimulating hormone in controlled ovarian hyperstimulation: a prospective, randomized, blinded clinical trial. Fertil Steril 2006; 86(5): 1428–31.CrossRefGoogle ScholarPubMed
Grabia, A, Papier, S, Pesce, R, Mlayes, L, Kopelman, S, Sueldo, C. Preliminary experience with a low-cost stimulation protocol that includes letrozole and human menopausal gonadotropins in normal responders for assisted reproductive technologies. Fertil Steril 2006; 86(4): 1026–8.CrossRefGoogle ScholarPubMed
Jee, BC, Ku, SY, Suh, CS, Kim, KC, Lee, WD, Kim, SH. Use of letrozole versus clomiphene citrate combined with gonadotropins in intrauterine insemination cycles: a pilot study. Fertil Steril 2006; 85(6): 1774–7.CrossRefGoogle ScholarPubMed
Bedaiwy, MA, Forman, R, Mousa, NA, Al Inany, HG, Casper, RF. Cost-effectiveness of aromatase inhibitor co-treatment for controlled ovarian stimulation. Hum Reprod 2006; 21(11): 2838–44.CrossRefGoogle ScholarPubMed
Verpoest, WM, Kolibianakis, E, Papanikolaou, E, Smitz, J, Steirteghem, A, Devroey, P. Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study. Reprod Biomed Online 2006; 13(2): 166–72.CrossRefGoogle ScholarPubMed
Cole, PA, Robinson, CH. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 1999; 33: 2933–44.CrossRefGoogle Scholar
Buzdar, A, Howell, A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001; 7: 2620–35.Google ScholarPubMed
Roberts, V, Meunier, H, Vaughan, J, et al. Production and regulation of inhibin subunits in pituitary gonadotropes. Endocrinology 1989; 124: 552–4.CrossRefGoogle ScholarPubMed
Mason, AJ, Berkemeier, LM, Schmelzer, CH, et al. Activin B: precursor sequences, genomic structure and in vitro activities. Mol Endocrinol 1989; 3: 1352–8.CrossRefGoogle ScholarPubMed
Weil, SJ, Vendola, K, Zhou, J, et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 1989; 837: 2479–85.Google Scholar
Weil, S, Vendola, K, Zhou, J, et al. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 1999; 848: 2951–6.CrossRefGoogle Scholar
Vendola, KA, Zhou, J, Adesanya, OO, et al. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998; 10112: 2622–9.CrossRefGoogle Scholar
Vendola, K, Zhou, J, Wang, J, et al. Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol Reprod 1999; 612: 353–7.CrossRefGoogle Scholar
Giudice, LC. Insulin-like growth factors and ovarian follicular development. Endocr Rev 1992; 13: 641–69.Google ScholarPubMed
Mitwally, MF, Bhakoo, HS, Crickard, K, Sullivan, MW, Batt, RE, Yeh, J. Estradiol production during controlled ovarian hyperstimulation correlates with treatment outcome in women undergoing in vitro fertilization-embryo transfer. Fertil Steril 2006; 86(3): 588–96.CrossRefGoogle ScholarPubMed
Mitwally, MF, Bhakoo, HS, Crickard, K, Sullivan, MW, Batt, RE, Yehl, J. Area under the curve for estradiol levels do not consistently reflect estradiol levels on the day of hCG administration in patients undergoing controlled ovarian hyperstimulation for IVF-ET. J Assist Reprod Genet 2005; 22(2): 57–63.CrossRefGoogle Scholar
Rizk, B, Aboulghar, M. Modern management of ovarian hyperstimulation syndrome. Hum Reprod 1991; 6(8): 1082–7.CrossRefGoogle ScholarPubMed
Bulun, SE, Zeitoun, KM, Takayama, K, Sasano, H. Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance. J Mol Endocrinol 2000; 1: 35–42.CrossRefGoogle Scholar
Vignali, M, Infantino, M, Matrone, R, et al. Endometriosis: novel etiopathogenetic concepts and clinical perspectives. Fertil Steril 2002; 784: 665–678.CrossRefGoogle Scholar
Nirmala, PB, Thampan, RV. Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol. Biochem Biophys Res Commun 1995; 2131: 24.CrossRefGoogle Scholar
Rosenfeld, CR, Roy, T, Cox, BE. Mechanisms modulating estrogen-induced uterine vasodilation. Vascul Pharmacol 2002; 382: 115.CrossRefGoogle Scholar
Oktay, K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol 2005; 23(16): 3858–9.CrossRefGoogle ScholarPubMed
Oktay, K, Buyuk, E, Libertella, N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23(19): 4347–53.CrossRefGoogle ScholarPubMed
Hamilton, A, Piccart, M. The third-generation nonsteroidal AIs: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 1999; 10: 377–84.CrossRefGoogle Scholar
Goss, PE. Risks versus benefits in the clinical application of aromatase inhibitors. Endocr Relat Cancer 1999; 6: 325–32.CrossRefGoogle ScholarPubMed
Palter, SF, Tavares, AB, Hourvitz, A, et al. Are estrogens of importance to primate/human ovarian folliculogenesis?Endocr Rev 2001; 223: 389–424.Google Scholar
Tiboni, GM. Aromatase inhibitors and teratogenesis. Fertil Steril 2004; 81: 1158–9.CrossRefGoogle ScholarPubMed
Tulandi, T, Al-Fadhli, R, Kabli, N, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 2006; 85(6): 1761–5.CrossRefGoogle ScholarPubMed
Hoffman, JIE. Incidence of congenital heart disease: I. Postnatal incidence. Pediatr Cardiol 1995; 16: 103.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×